CME Tweetorial on pan-tumor HER2 Testing

Twitter (X) for CME! 

Here is a CME Tweetorial on the topic of pan-tumor HER2 in advanced gynecologic cancers. Read through these threaded tweets: x.com/ASCP_Chicago/status/1826660024975782312

Claim CME credit here: t.co/iJjqlWc47f​

Rate your level of familiarity with pan-tumor HER2 biomarker testing in patients with advanced solid tumors.#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Investigator-assessed ORRs (objective response rate) was 57.5% for endometrial (95% CI, 40.9 to 73.0); 50.0% for cervical (95% CI, 33.8 to 66.2); 45.0% for ovarian (95% CI, 29.3 to 61.5) in DESTINY-PanTumor02. https://t.co/IX3C4o1kjY#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

ADCs like T-DXd have unique toxicity profiles. Vigilant monitoring required for patients receiving treatment. https://t.co/yzi8aQo1FP#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Differences in HER2 overexpression may be observed when using different IHC antibodies in ovarian and endometrial clear cell carcinoma (CCC). https://t.co/GrcjFpZC3C#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

In DESTINY-PanTumor02 the ASCO/CAP guidelines for scoring HER2 in gastric cancer were used to assess results. https://t.co/g61yYDb9J7#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Read this article that outlines some practical considerations when implementing a pan-tumor HER2 IHC test in the laboratory: https://t.co/vYAP1Uq29J#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Patients with advanced HER2-positive (IHC 3+) cervical, endometrial, and ovarian cancers may be considered for treatment based on the FDA accelerated approval of T-DXd for this indication. https://t.co/EtEWxs0INY#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Thank you for participating in this CME Tweetorial on pan-tumor HER2 testing! Claim your CME credit here: https://t.co/fLFjXx0Gur

Stay tuned as ASCP releases more education on this topic in the coming months!#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024